Image via Wikipedia Radient Pharmaceuticals (AMEX: RPC) is having one impressive day. Today it announced target market details for the commercialization of its Onko-Sure in vitro diagnostic cancer test. It received approval FDA approval 24 months ago and has been validating test kits for oncologists, gastroenterologists, and lab directors for use. The company is now in position for marketing and commercializing Onko-Sure technology.
